Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution
Gothenburg, October 18, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that it has entered a Material Transfer Agreement with the Josep Carreras Leukaemia Research Institute (“JCLRI”) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. The agreement is the first to be executed as part of Elicera’s strategy of finding collaborators and licensing partners for iTANK.Following